[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-neuroendocrine-tumors-pnet\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-neuroendocrine-tumors-pnet":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,78,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100639971","phase-3-long-term-extension-study-for-participants-previously-enrolled-in-an-exelixis-sponsored-study-100639971",false,"NCT07620574","Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","Key Inclusion Criteria:\n\n* Eligible to continue receiving the study treatment in the parent study (that is, has not met parent study discontinuation\u002Fwithdrawal criteria).\n* Continuing to derive clinical benefit from the study treatment at the time of transition from the parent study as assessed by the investigator.\n* Able to comply with the long-term extension study protocol as determined by the investigator.\n* Able to receive the first dose of study treatment in this extension study within the specified treatment interruption window allowed by the parent study.\n\nKey Exclusion Criteria:\n\n* Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study.\n* Study treatment is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant.\n* Treatment with any anticancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study.\n* Permanent discontinuation of all study treatment(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study (if applicable).\n* Concurrent participation in any therapeutic clinical trial (other than the parent study).\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL",{"count":17,"type":18},5000,"ESTIMATED","INTERVENTIONAL",[21],"PHASE3","The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.",[24,25,26,27,28,29,30,31,32],"Cancer","Renal Cell Carcinoma (RCC)","Pancreatic Neuroendocrine Tumors (pNET)","Extra-Pancreatic NET (epNET)","Hepatocellular Carcinoma (HCC)","Differentiated Thyroid Cancer (DTC)","Non-Clear Cell Renal Cell Carcinoma (nccRCC)","Colorectal Cancer","Prostate Cancer",[25,26,27,28,29,30,31],"NOT_YET_RECRUITING","2026-05-27",{"date":37,"type":38},"2026-06-02","ACTUAL",{"date":40,"type":18},"2026-05-31",{"date":42,"type":18},"2030-05-31",{"name":44,"class":45},"Exelixis","INDUSTRY",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":19,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100640660","phase-3-adjuvant-trial-in-pancreatic-neuroendocrine-tumors-100640660","NCT07591493","Adjuvant Trial in Pancreatic Neuroendocrine Tumors","First Adjuvant Trial in Locally Resected Aggressive Pancreatic Neuroendocrine Tumors: a Randomized Phase III Investigating the Efficacy of Systemic Chemotherapy","ADJUPANET","Inclusion Criteria:\n\n1. Pathologically proven well differentiated neuro-endocrine tumour of the pancreas by local teams\n2. Availability of the primary tumor specimen, allowing accurate WHO classification and determination of MGMT status\n3. Stage I-III based ENETS-UICC 8th classification\n4. Early postoperative context (≤ 4 months)\n5. R0 resection\n6. Absence of distant metastasis or local tumor remnant as defined by a negative post-operative thorax CT and -abdomen CT or MRI and negative (best of DOTA-peptide 68Ga or, FDG) PET imaging if performed preoperatively\n7. ECOG 0-1\n8. No prior systemic therapy\n9. Intermediate to high risk of recurrence as defined by the following situations:\n\n   * Ki67 ≥ 10% (i.e.: Grade 3 or high Ki67 Grade 2)\n   * Ki67 5-9% AND (tumor size \\> 3 cm OR Node positive)\n   * Ki67 3-5% AND tumor size \\> 3 cm AND Node positive\n   * Ki67 \\\u003C 3% AND tumor size \\> 3 cm AND Node positive AND (Vascular Emboli OR perineural invasion)\n10. Age ≥ 18 years at the time of consent, no superior limit\n11. Adequate bone marrow reserve (hemoglobine \\> 8 g\u002FdL, absolute neutrophils count ≥ 1500\u002Fmm³ and platelets ≥ 80 000\u002Fmm³)\n12. Effective contraception\n13. Written, dated and signed informed consent by the patient prior to any specific protocol procedure\n14. Ability to comply with the protocol procedures\n15. Patient affiliated to a social security system or beneficiary of the same\n\nExclusion Criteria:\n\n1. Poorly differentiated tumours (NEC)\n2. Mixed NeuroEndocrine Non NeuroEndocrine tumors (MiNEN)\n3. Neoadjuvant treatment or treatment with chemotherapy regimen used for another malignancy\n4. Pregnant women or breastfeeding women\n5. ECOG performance status \\> 1\n6. Age \\\u003C 18 years\n7. PanNET arising in a genetic syndrome with other NETs already diagnosed (NF1, VHL or MEN)\n8. History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least five years\n9. Severe renal insufficiency (measured GFR according to MDRD \\\u003C 30 ml\u002Fmn or nephrotic syndrome) or hepatic insufficiency (ALT \u002F AST \\> 2.5 x ULN or ALT\u002FAST \\> 5 x ULN if liver function abnormalities are due to the underlying malignancy and\u002For total serum bilirubin \\> 2.5 x ULN)\n10. Serum albumin \\\u003C 3.0 g\u002FdL unless prothrombin time is within the normal range\n11. Current treatment with another investigational drug\n12. Unrecovered toxicity from surgery\n13. Active or suspected acute or chronic uncontrolled disease that would impart, in the judgment of the Investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the Investigator, would make the patient inappropriate for entry into this study\n14. Dihydropyrimidine dehydrogenase (DPD) deficiency or not done\n15. Recent or concomitant treatment with brivudine\n16. Hypersensitivity to Capecitabine or Temozolomide or to any of the excipients","18 Years",{"count":56,"type":18},300,[21],"ADJUPANET is an open label, double arm, multicenter, phase 3 trial that aims to investigate the efficacy of systemic chemotherapy in locally resected aggressive pancreatic neuroendocrine tumors. The two arms of patients are the following : i. control arm : active surveillance only, standard of care. ii. experimental arm : adjuvant chemotherapy with 6 cycles of CAPECITABINE-TEMOZOLOMIDE (per os) and active surveillance. Patients enrolled in the experimental arm will receive Capecitabine CAPECITABINE per os 750 mg\u002Fm² (twice a day: D1 to D14) D1=D28 and TEMOZOLOMIDE per os 200 mg\u002Fm² (once a day: D10 to D14) D1=D28.",[26,60],"Pancreatic Neuroendocrine Tumors",[62,63,64,65,66],"R0 resected","stage I-III","CAPECITABINE","TEMOZOLOMIDE","active surveillance","2026-05-11",{"date":69,"type":38},"2026-05-15",{"date":71,"type":18},"2026-09",{"date":73,"type":18},"2035-06",{"name":75,"class":76},"Gustave Roussy, Cancer Campus, Grand Paris","OTHER",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":19,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":77},"100634161","endoscopic-ultrasound-guided-radiofrequency-ablation-for-pancreatic-cystic-neoplasms-and-pancreatic-neuroendocrine-tumors-100634161","NCT07536087","Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors","Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Neuroendocrine Tumors","Inclusion Criteria:\n\n* Consensual indication to EUS-guided RFA treatment made in a multidisciplinary team\n* Capability of giving informed consent PCN Inoperability or refusal of surgery\n* Branch duct IPMN (BD-IPMN) with worrisome features:\n* Jaundice\n* High grade dysplasia or cancer\n* Solid mass\u002Fnodule \\> 5mm\n* Main pancreatic duct dilation \\> 10mm Or at least one (patients without comorbidities) or at least two (patient with comorbidities) of the following risk features:\n* CA 19-9\\> 37 U\u002Fml\n* Increase in size \\> 5mm\u002Fyear\n* Dilation of the main pancreatic duct between 5-10mm\n* Size ≥ 40mm\n* Symptoms (new onset of diabetes, acute pancreatitis)\n* Nodule \\\u003C 5mm Pancreatic NET\n* Size \\\u003C 2 cm\n* Histological proof in non-functional lesions\u002Fhistological proof or clinical proof in functional lesions\n* 68Ga-DOTATATE PET\u002FCT positive for a pancreatic lesion and negative for lymph nodes, liver, and other distant metastases\n* G1 or G2 (\\\u003C5 %) histology\n\nExclusion Criteria:\n\n* Known bleeding disorder that cannot be sufficiently corrected with medication\n* Use of anticoagulants that cannot be discontinued\n* Physical and\u002For psychological inability to understand the aims of the research and to adequately cooperate\n* Pregnancy\n* Inability to sign the informed consent",{"count":86,"type":18},50,[88],"NA","The primary aim of this study is to evaluate the technical feasibility and effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) in the treatment of pancreatic cystic neoplasms (PCNs) and pancreatic neuroendocrine tumors (pNETs) in patients who are not suitable candidates for surgical treatment or who refuse surgery.\n\nEUS-RFA, as a minimally invasive therapeutic option, may potentially reduce the need for intensive imaging surveillance, prevent further progression of these lesions, and serve as a bridging therapy in selected patients for whom surgical intervention may be considered in the future. At the same time, EUS-RFA could contribute to reducing overtreatment, thereby lowering the risk of complications associated with surgical procedures and leading to an overall reduction in healthcare costs.\n\nThe secondary objectives of the study are to evaluate the safety profile of EUS-RFA, including the incidence and severity of adverse events both in the early postoperative period and during the first year of follow-up, as well as to assess the long-term efficacy of EUS-RFA, including disease progression.",[91,26,92],"Endoscopic Ultrasound-Guided Radiofrequency Ablation","Pancreatic Cystic Neoplasms",[94,95,96,97,98,99],"Pancreatic Cystic Neoplasm","Intraductal papillary mucinous neoplasm","EUS-guided RFA","Pancreas","Neuroendocrine tumor","Radiofrequency ablation","RECRUITING","2026-04-11",{"date":103,"type":38},"2026-04-17",{"date":101,"type":38},{"date":106,"type":18},"2029-12-31",{"name":108,"class":109},"Institute for Clinical and Experimental Medicine","OTHER_GOV",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":19,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":77},"100614058","superb-microvascular-imaging-smi-and-two-dimensional-endoscopic-ultrasound-guided-shear-wave-elastography-2d-swe-eus-in-differential-diagnosis-of-pancreatic-adenocarcinoma-pa-from-other-pancreatic-solid-lesions-psls-and-pancreatic-neuroendocrine-tumors-pnets-malignancy-100614058","NCT07274657","Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy","SMILE","Inclusion Criteria:\n\n* Patient, male or female, age ≥ 18 years old\n* Patient with diagnosed pancreatic solid or mixed (cystic component ≤25 % of tumor volume) lesion\n* Patient with adequate understanding of written and spoken French, able to sign written informed consent\n* Patient affiliated with a social security system\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Patient with usual contraindications to EUS- TA\n* Patient with usual contraindications to SonoVue® administration\n* Patient with a genetic syndrome associated pancreatic lesion (multiple neuroendocrine neoplasia type 1 (MEN1), type 1 neurofibromatosis (NF), Von-Hippel Lindau (VHL) disease)\n* Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision.\n* Patient unable to perform the monitoring",{"count":118,"type":18},150,[88],"Pancreatic adenocarcinoma (PA) is the most common tumor of the pancreas. Given its poor prognosis and the major therapeutic consequences, the discrimination between PA and other pancreatic solid lesions is mandatory.\n\nEndoscopic ultrasound (EUS) is admitted as the most sensitive imaging procedure for the detection and characterization of pancreatic tumors. Over the past 30 years, EUS-guided tissue acquisition (EUS-TA), or more recently fine needle biopsy (EUS-FNB), has demonstrated its efficiency for tissue sampling and remains the gold standard for the pathologic diagnosis of pancreatic lesions.\n\nThe assessment of pancreatic tumor enhancement using ultrasound contrast agents (UCAs) in real time with imaging specific methods seems useful to improve their characterization either by contrast-enhanced EUS (CE-EUS) or, more recently, by contrast-harmonic EUS (CH-EUS). CH-EUS was already demonstrated useful to differentiate pancreatic adenocarcinoma from other pancreatic lesions.\n\nEUS-Elastography (EUS-E) is another EUS image enhancement technique, which rational based on the difference in elasticity between the tissues. There are two types of elastographies: strain elastography (SE) and shear wave elastography (SWE). SE has proved useful for the characterization of pancreatic lesions and lymph nodes. However, this technique was demonstrated difficult to perform with adequate accuracy and reproducibility for pancreatic lesions and have many limitations. In some recent publications SWE was demonstrated moderate reliability.\n\nPancreatic neuroendocrine tumors (pNETs) are rare tumors, but according to the last epidemiological data, their incidence and prevalence are steadily rising.\n\nSurgical resection is generally performed for pNETs due to their malignant potential. However, with increasing use of high-resolution conventional imaging, the significant incidence of small (≤ 2 cm) pancreatic neuroendocrine incidentaloma (pNET) has risen in recent decades.\n\nEUS is recognized as the most sensitive procedure for the detection and characterization of pNETs. Overall sensitivity of EUS-TA for the diagnosis of pNETs is high, reaching 95.1% in recently published study, appearing higher in small lesions (≤ 20 mm) than in large lesions (\\> 20 mm).\n\nThe overall concordance rate for EUS-TA and surgical specimens grading varies from 58% to 86.4% and is higher for lesions ≤ 10 mm, 10-20 mm, comparing to lesions \\> 20 mm. These results confirm the risk of under or over-grading of pNETs on the EUS-TA specimen, independently of the needle size which used for the TA.\n\nCH-EUS was also demonstrated accurate in the prediction of pNETs malignancy and useful for decision-making management of these tumors.\n\nHypothesis\n\nTwo new image enhancement EUS technologies were recently developed, able to assess precisely tumor microvascular density and the stiffness of pancreatic lesions, that is correlated to tumor's stroma fibrosis, and thus help to characterize and predict the malignancy, and accordingly, the management of the pancreatic solid lesions. It's particularly useful in overcoming EUS false-negative cases of PA and small pNETs malignancy diagnosis.\n\nSuperb Microvascular Imaging (SMI) is a novel doppler technique that enhances the range of visible blood flow, by revealing low velocity microvascular flow, enabling the capture of a higher-quality microvascular flow images. Based on the same principle as CH-EUS, which assesses tumor microvascularization, this technique is expected to be also useful for the PSLs malignancy diagnosis.\n\nShear Wave Elastography (SWE) relies on the properties of shear-wave propagation to offer an advanced assessment of their velocity",[122,26],"Pancreas Adenocarcinoma (MSI-H)","2025-12-09",{"date":125,"type":38},"2025-12-10",{"date":127,"type":18},"2026-01-01",{"date":129,"type":18},"2028-06-30",{"name":131,"class":76},"GCS Ramsay Santé pour l'Enseignement et la Recherche"]